Abstract library

298 results for "Fernandez del Valle".
#2235 Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)
Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: PhD Paula Jimenez-Fonseca
#2277 Neuroendocrine Tumors Committee of Reference Hospital: Decision-Making Process on the Diagnostic and Therapeutic Approach to Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) require a multidisciplinary approach in expert centers due to their rarity, heterogeneity and the lack of evidence about optimal clinical management.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PhD Paula Jimenez-Fonseca
#2217 Prognostic Impact of CHOI Response Criteria Compared to RECIST in Grade 1-2 Advanced Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study-NCT02841865)
Introduction: Response Evaluation Criteria In Solid Tumors (RECIST) are not presumably the most optimal option for predicting the benefit of antiangiogenic drugs in neuroendocrine tumors (NETs), given that tumor shrinkage is not frequent, and qualitative changes in tumor tissues are to be expected.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: PhD Paula Jimenez-Fonseca
#775 Whole Exome Sequence Of BON-1 And QGP-1, Two Human Pancreatic Neuroendocrine Tumor Cell Lines, Reveals Homozygous Loss Of Function Mutations In TP53, HRNR and CYFIP2.
Introduction: The human BON-1 and QGP-1 cell lines are two models often used in pancreatic neuroendocrine tumor (PNET) research. Data on protein-changing mutations in these cell lines is lacking.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Timon Vandamme
#1532 Epidemiology, Pathological Features and Clinical Outcome of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): Results from the National Neuroendocrine Cancer Registry of Spain (R-GETNE)
Introduction: The Spanish National Neuroendocrine Cancer Registry is a hospital-based registry of GEP-NENs coordinated by the scientific multidisciplinary Spanish society GETNE, that covers 57 academic and community sites representing all regions of Spain.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PhD Paula Jimenez-Fonseca
#1799 Pilot Electronic Survey to Locate Nurses Caring for NET Patients in Europe.
Introduction: There is an assumed variance in the roles nurses have in looking after NET patients, and the different levels of knowledge.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: Philippa Davies
#455 Depression and Carcinoid Syndrome: Is There Any Relationship? A Cross-Sectional Study
Introduction: The relationship between brain serotonin and depression is well-established. It is also widely accepted that serotonin hyperproduction in carcinoid syndrome does not cross the brain barrier. CNS serotonin is synthesised from tryptophan within serotonergic neurons and a deficiency of this precursor could be possible on carcinoid patients.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mr Jorge Garcia-Hernandez
#1153 Prognostic Role of Diabetes Mellitus (DM) and Metformin (MET) Therapy in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs) Treated with Everolimus (EVE)
Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio
#1301 Role of TSC22D1 (TGFβ-Stimulated Clone 22 Domain Family Member 1) in Bronchial Carcinoids
Introduction: Neuroendocrine tumors (NETs) include bronchial carcinoids, either typical (TC) or atypical (AC). Tsc22d1 encodes for a member of TSC22 domain family of leucine zipper transcription factors; the protein (TSC22D1) is stimulated by TGFβ. Microarray data analysis obtained comparing a pool of TC tissue specimens with a pool of AC tissue specimens shows TSC22D1 down-regulation in AC samples. These data were confirmed by real time PCR and Western blot in vitro models of TC (NCI-H727 cells) and AC (NCI-H720 cells)
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: PhD student Simona Falletta
#1358 Identifying and Prioritising Gaps in Neuroendocrine Tumour Research - Results of the Delphi Consensus Project of the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETS)
Introduction: The newly formed CommNETS group used the robust Delphi methodology with broad stakeholder engagement to form a strategic research agenda.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: A/P Eva Segelov
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.